Access to anti-retroviral drugs, female in Rwanda

Rwanda: Access to anti-retroviral drugs, female was 97.0% in 2024. ◆ Volatile

Latest (2024)
97.0%
Change on year
up 4.3%
World rank
12th
of 141 countries
All-time high
97.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Rwanda, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 3 %2005: 9 %2006: 16 %2007: 21 %2008: 28 %2009: 34 %2010: 39 %2011: 43 %2012: 51 %2013: 56 %2014: 62 %2015: 68 %2016: 75 %2017: 77 %2018: 80 %2019: 82 %2020: 85 %2021: 88 %2022: 91 %2023: 93 %2024: 97 %

Source: UNAIDS estimates. Measured in %.

Analysis

Rwanda recorded 97.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 4.3% on the previous year and up 56.5% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Rwanda peaked at 97.0% in 2024 and was at its lowest, 0.0%, in 2000.

Rwanda ranks 12th of 141 countries on this measure, in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Rwanda, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Rwanda, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 3.0%
2005 9.0% +200.0%
2006 16.0% +77.8%
2007 21.0% +31.2%
2008 28.0% +33.3%
2009 34.0% +21.4%
2010 39.0% +14.7%
2011 43.0% +10.3%
2012 51.0% +18.6%
2013 56.0% +9.8%
2014 62.0% +10.7%
2015 68.0% +9.7%
2016 75.0% +10.3%
2017 77.0% +2.7%
2018 80.0% +3.9%
2019 82.0% +2.5%
2020 85.0% +3.7%
2021 88.0% +3.5%
2022 91.0% +3.4%
2023 93.0% +2.2%
2024 97.0% +4.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 11.1% 0.0% 34.0% 10
2010s 63.3% 39.0% 82.0% 10
2020s 90.8% 85.0% 97.0% 5

Countries ranked near Rwanda

  1. 12 United Arab Emirates 97.0% compare
  2. 14 Liberia 96.0% compare
  3. 14 Sweden 96.0% compare
  4. 14 Togo 96.0% compare
  5. 14 United Kingdom of Great Britain and Northern Ireland 96.0% compare
  6. 14 Zambia 96.0% compare

See the full ranking of 160 places →

More gender data for Rwanda

All data for Rwanda →

Frequently asked questions

What is access to anti-retroviral drugs, female in Rwanda?
Access to anti-retroviral drugs, female in Rwanda was 97.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Rwanda?
The highest recorded value was 97.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Rwanda?
The lowest recorded value was 0.0% in 2000.
How does Rwanda rank for access to anti-retroviral drugs, female?
Rwanda ranks 12th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Rwanda?
Over the last ten years it is up 56.5%. The long-run trend across the full record is volatile.
Where does this Rwanda data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Rwanda. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/rwanda/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/rwanda/">Access to anti-retroviral drugs, female in Rwanda</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.